Belite Bio Inc
Company Profile
Business description
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Contact
12750 High Bluff Drive
Suite 475
San DiegoCA92130
USAT: +1 858 246-6240
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
41
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.90 | 24.70 | -0.27% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,695.62 | 354.89 | 1.46% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,554.30 | 810.80 | 1.20% |
| NZX 50 Index | 13,595.52 | 55.70 | -0.41% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,830.30 | 26.70 | -0.30% |
| SSE Composite Index | 3,963.90 | 3.22 | -0.08% |